Lipiodal
Phase 1Small molecule
Lipiodal is one of 10 small molecule programs targeting Adjuvant. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Adjuvant
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Ibrance
PfizerPhase 3
Imjudo
AstraZenecaPhase 3
Afinitor
NovartisPhase 3
Bavencio
EMD SeronoPhase 3
Standard Adjuvant Endocrine Therapy
Eli LillyPhase 3
Isoproterenol Hydrochloride
SanofiPhase 1
Poly ICLC
CCelldex Therapeutics
Phase 1
CDX-301
CCelldex Therapeutics
Phase 1
Lipiodal
WWestern University, Canada
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lipiodal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- WWestern University, Canada